Hanmi Pharmaceutical, J&J deal

Hanmi granted Johnson & Johnson’s Janssen Pharmaceuticals Inc. unit exclusive, worldwide rights outside of China and Korea to develop and commercialize oxyntomodulin-based therapies, including HM12525A, to treat diabetes and obesity. Hanmi will receive $105 million up front and is eligible for up to $810 million in clinical, regulatory and sales milestones, plus tiered double-digit royalties. ...